The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel StatementVasilios G. Athyros, Christos S. Mantzoros, Theodore K. Alexandrides et al.|Metabolism|2017Cited by 251
“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL SubclassesDimitri P. Mikhailidis, Evangelos Liberopoulos, Alexandros D. Tselepis et al.|Current Vascular Pharmacology|2011Cited by 197
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemiaRoberto Ferrari, Alberico L. Catapano, Carlos Aguíar et al.|European Heart Journal Supplements|2016Cited by 101
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapyCarlos Aguíar, Roberto Ferrari, Eduardo Alegría et al.|Atherosclerosis Supplements|2015Cited by 84
Effects of hormonal treatment on lipids in patients with cancerTheodosios D. Filippatos, D.P. Mikhailidis, Evangelos Liberopoulos et al.|Cancer Treatment Reviews|2008Cited by 62